Lenvatinib Suppliers & Bulk Manufacturers
Available Forms: Oral capsules
Available Strengths: 4 mg , 10 mg
Reference Brands: Lenvima® (EU & US)
Category:
Oncology Cancer Care
Lenvatinib (brand name Lenvima®) is an oral tyrosine kinase inhibitor used to treat thyroid cancer, RCC, HCC, and endometrial cancer. Available in 4 mg and 10 mg capsules, it’s approved in the US and EU. Widely sourced by B2B pharma suppliers, Lenvatinib ensures GMP-compliant, reliable supply for oncology centers with competitive pricing.
Lenvatinib is available in Oral capsules
and strengths such as 4 mg , 10 mg.
Sourced from GMP-certified and ISO-compliant manufacturers, this API meets
global pharmacopeia standards (USP/EP/JP as applicable). Ideal for pharmaceutical
formulation and commercial manufacturing, Lenvatinib is supplied in
bulk quantities with complete regulatory support including DMF, COA, and MSDS.
|
Technical Specifications & Supply Details
|
| Lead Time |
7 to 60 days (depending on batch size & schedule) |
| MOQ |
As per manufacturer’s batch size |
| COA |
Available with every batch |
| Regulatory Dossier / DMF |
Available upon request |
| Export Documentation |
FSC, COA, Manufacturing License, Product Permission |
| Standards |
IP, BP, USP |
| Certifications |
WHO-GMP, EU-GMP, USFDA (as applicable) |
Lenvatinib can be exported to over 30 countries across Asia, Africa, Europe,
and Latin America. Flexible packaging, competitive pricing, and a verified supplier
network make Pharmatradz a trusted sourcing partner for pharmaceutical companies
and contract manufacturers worldwide.
Product Description:
Lenvatinib, marketed as Lenvima® by Eisai, is a potent oral tyrosine kinase inhibitor (TKI) used in oncology to treat thyroid cancer, renal cell carcinoma (RCC), hepatocellular carcinoma (HCC), and endometrial carcinoma. Available in 4 mg and 10 mg capsules, Lenvatinib is approved in both the US and EU. It works by inhibiting tumor angiogenesis and cell proliferation. As a high-demand anticancer therapy, it is widely distributed by pharma B2B suppliers across the European and U.S. markets, ensuring GMP-compliant sourcing, consistent availability, and competitive pricing for hospitals, pharmacies, and oncology centers managing advanced cancers.
Disclaimer: By continuing to browse, you agree to the terms of use of this website and the Trade Marks displayed, in compliance with the provisions of the Trademark Act, 1999, Section 30 and 30(1) under 'Fair use.'
The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Back to Listing